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Abstract
Every year, millions of people undergo percutaneous coronary intervention (PCI) with
intracoronary stent implantation. A patient from the PRAGUE-8 trial (Optimal pre-PCI clopidogrel
loading: 600 mg before every coronary angiography vs. 600 mg in the cath-lab only for PCI patients)
is described who suffered from acute stent thrombosis. This patient did not have any relevant
inhibition of platelet activation even after the 600 mg dose of clopidogrel. Dose uptitration would
have been ineffective. New P2Y12 receptor inhibitors are desperately needed. In the light of
recently published data, the use of prasugrel may be considered as an alternative.
Introduction
Every year, millions of people undergo percutaneous cor-
onary intervention (PCI) with intracoronary stent implan-
tation. Dual antiplatelet therapy – aspirin plus clopidogrel
– is recommended for the reduction of acute and subacute
stent thrombosis [1,2]. Despite combined antiplatelet
therapy, stent thrombosis persists at a rate of 0.5–2% in
elective cases, and up to 6% in patients with acute coro-
nary syndromes [3]. Stent thrombosis is a life-threatening
event [4]. In addition, also in cases of immediate reper-
fusion therapy by means of emergency PCI, patients with
stent thrombosis have developed a major myocardial inf-
arction, with consequent significant decline in left ven-
tricular function – a strong negative predictor of long-term
survival [3]. "Retrospective" laboratory testing in patients
with stent thrombosis has shown that poor response
("resistance") to antiplatelet therapy is a risk factor for this
event [5-7].
Case report
A 67-year old woman was admitted to Cardiocentre for an
elective coronary angiography, because of changes on the
ECG (new negative T waves in leads I, aVL, V1-V3) and
new anteroapical hypokinesis seen by echocardiography.
She was a cigarette smoker, with a history of diabetes,
hypertension, hypercholestrolemia on statin therapy
(atorvastatin), and with known coronary artery disease on
aspirin. The patient fulfilled the inclusion criteria of the
PRAGUE-8 trial (see section methods) [8]. After signing of
informed consent, she was randomized into group B of
this study, and also participated in the vasodilator stimu-
lated phosphoprotein (VASP) phosphorylation state and
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genetic laboratory substudies. In the laboratory substudy,
the time course of platelet inhibition after clopidogrel
(600 mg loading dose followed by 75 mg per day) was
investigated.
On the second day of hospitalization, the patient under-
went a coronary angiography, which showed an 80%
stenotic lesion on her left anterior descending artery. The
lesion was treated with ad hoc performed PCI with the
implantation of a bare metal stent. The success of the pro-
cedure was optimal (Figure 1A, B). The next day, the
patient was stable, did not have any complications, and
was discharged home. The recommendation for drug ther-
apy was as follows: ASA (100 mg/d), clopidogrel (75 mg/
d), metoprolol, ramipril, atorvastatin, peroral antidia-
betic.
46 hours after stent implantation, the patient returned to
the hospital because of chest pain, vertigo and swelling.
There were ST segment elevations in leads V1-V3 and a
new second-degree A-V block according to the ECG (Fig-
ure 2). An emergency coronary angiography was per-
formed, and showed 100% occlusion of the left anterior
descending artery due to acute stent thrombosis. Immedi-
ate ballon angioplasty with heparin and eptifibatide
opened the artery and led to a good angiographic result
(Figure 1C, D).
What did the VASP phosphorylation study show? There
was no reaction to the administration of clopidogrel – the
patient was completely "resistant" to this drug (Figure 3).
Interestingly, by the second admission the ADP-stimu-
lated platelet reactivity was even higher than the basal
value without clopidogrel therapy. The most probable
Coronary angiography and pecutaneous coronary intevention studies Figure 1
Coronary angiography and pecutaneous coronary intevention studies. A, B – elective during the first hospitalization; 
C, D – urgent during the second hospitlization.Thrombosis Journal 2009, 7:6 http://www.thrombosisjournal.com/content/7/1/6
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explanation for this was an acute myocardial infarction,
which was the reason for the second hospitalization.
In the genetic substudy we investigated the prevalence of
nine platelet and haemostatic gene polymorphisms. The
results of this extensive genetic testing are shown in Table
1. Detected single nucleotid polymorphisms of P2Y12 and
GPIIIa receptors had been recognized as possible intrinsic
mechanisms of clopidogrel resistance [8,9].
Methods
The PRAGUE-8 study was a randomized multi-center open
label clinical trial which compared the routine clopidogrel
600 mg pretreatment more than 6 hours before coronary
angiography (group A) with the selective administration
of clopidogrel 600 mg only for PCI patients in the cathe-
terization laboratory, after the coronary angiography and
just prior to PCI (group B) (ClinicalTrials.gov identifier
NCT00432120) [10]. The inclusion criteria were: a
planned elective coronary angiography for suspected or
proven chronic stable coronary artery disease or medically
fully stabilized acute coronary syndrome, a signed written
informed consent, and age ≥ 18 years. The primary end
point was the first clinical occurrence of any of the follow-
ing: death, periprocedural myocardial infarction, stroke or
transient ischemic attack, or re-intervention within 7 days.
Secondary end-points were: periprocedural troponin ele-
vation (> 3 × ULN), TIMI-flow after PCI, bleeding compli-
cations, and each individual component of the combined
primary end-point.
Vasodilator Stimulated Phosphoprotein (VASP) is a platelet
intracellular actin regulatory protein. The phosphoryla-
tion of VASP is regulated by the cyclic adenosine mono-
phosphate cascade. Prostaglandin E1  activates this
cascade, whereas it is inhibited by adenosine diphosphate
through P2Y12 receptors. The phosphorylation status of
VASP correlates with P2Y12 receptor inhibition, whereas
its non-phosphorylation state correlates with the active
form of the P2Y12 receptor. Levels of VASP phosphoryla-
tion/dephosphorylation reflect P2Y12  inhibition/activa-
tion [11]. The effect of thienopyridines can be
demonstrated by the persistence of VASP phosphoryla-
ECG at the second hospital admission Figure 2
ECG at the second hospital admission.Thrombosis Journal 2009, 7:6 http://www.thrombosisjournal.com/content/7/1/6
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tion induced by prostaglandin E1, even with the simulta-
neous addition of ADP [12,13].
Analysis of VASP phosphorylation by flow cytometry. Flow
cytometry analysis was done in a laboratory awarded by
the Joint Commission International accreditation. Exam-
iners analyzing the VASP phosphorylation state were
blinded to the patient-related data. The VASP phosphor-
ylation state was determined in whole blood by flow
cytometry using the standardized (CE, IVD) platelet
VASP/P2Y12 assay (Biocytex, France). Briefly, the blood
sample was first incubated with prostaglandin E1 alone or
prostaglandin E1 + ADP. After cellular permeabilization,
VASP under its phosphorylated state was labeled by indi-
rect, no-wash immunofluorescence using a specific mon-
oclonal antibody (16C2). Dual-color flow cytometric
analysis was performed on a Becton Dickinson FACS Cal-
ibur cytometer to compare the two tested conditions, and
to evaluate the capacity of ADP to inhibit VASP phospho-
rylation for each sample. The platelet population was
identified by forward scatter, side scatter and fluorescence
(anti CD61-PE) gating, then 5000 events were acquired at
low rate to list mode files.
A platelet reactivity index (PRI) was calculated from the
median fluorescence intensity (MFI) of samples incubated
with prostaglandin E1  or prostaglandin E1  and ADP,
according to the formula: PRI = [(MFI(PGE1)  -
MFI(PGE1+ADP)/MFI(PGE1)] × 100. If inhibition of the plate-
let P2Y12 receptor by clopidogrel occurs, ADP fails to cause
Clopidogrel efficacy; ADP-induced platelet activation (Platelet reactivity index) [11] before and after clopidogrel Figure 3
Clopidogrel efficacy; ADP-induced platelet activation (Platelet reactivity index) [11]before and after clopidog-
rel.Thrombosis Journal 2009, 7:6 http://www.thrombosisjournal.com/content/7/1/6
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a decrease in VASP phosphorylation and the PRI con-
verges to 0. In contrast, if treatment is ineffective (i.e. a
low responder), dephosphorylation of VASP by ADP still
occurs, and the PRI reaches values of ≥ 0.5 or greater [11].
Discussion
How should this patient be managed? What do the recom-
mendations say? We have only the expert consensus posi-
tion regarding aspirin resistance [14]. There is no official
expert statement on the problem of clopidogrel ineffec-
tiveness or resistance. The ACC/AHA guidelines recom-
mends that "in patients in whom subacute thrombosis
may be catastrophic or lethal, platelet aggregation studies
may be considered and the dose of clopidogrel increased
to 150 mg per day if less than 50% inhibition of platelet
aggregation is demonstrated" [2].
As Figure 3 shows, our patient did not have any relevant
inhibition of ADP-induced platelet reactivity even after
the 600 mg clopidogrel. Therefore, dose up-titration
would have been ineffective. Administration of GPIIb/IIIa
inhibitor during emergency PCI for stent thrombosis has
been identified as the only independent predictor for the
prevention of recurrent stent thrombosis [3]. Third gener-
ation tienopyridine prasugrel provides faster onset and
greater inhibition of P2Y12  receptor-mediated platelet
aggregation than clopidogrel, because of greater and more
efficient generation of the active metabolite [15,16]. Phar-
macodynamic data have also shown that prasugrel
achieves a sufficient degree of platelet inhibition within
30 minutes after treatment [14]. In a crossover study, non-
responders to 300 mg of clopidogrel responded effectively
to a loading dose of 60 mg of prasugrel [17]. This favora-
ble laboratory profile resulted in clinical efficacy for
prasugrel. The TRITON-TIMI 38 [18] trial recently showed
that in comparison to clopidogrel, prasugrel therapy was
associated with significantly reduced rates of ischemic
events in patients with acute coronary syndromes with
scheduled PCI. Stent thrombosis was reduced by approxi-
mately 50% in the prasugrel group compared to the clopi-
dogrel group. The price for this clinical benefit was a
significantly higher risk of major bleeding.
In patients with planned elective PCI for whom the opti-
mal time for clopidogrel pretreatment is a day before pro-
cedure [19], a test for drug effectiveness before the
procedure will identify patients with insufficient platelet
inhibition. In these patients, the administration of GPIIb/
IIIa inhibitors during the procedure and a higher dose
(150 mg per day) of clopidogrel after stent implantation
should be advised to prevent stent thrombosis [2,3]. In
patients with no response to the clopidogrel loading dose,
prasugrel seems to be an effective alternative [15-18,20].
Flow cytometric determination of VASP phosphorylation
state strongly correlated with the inhibition of ADP-
induced platelet aggregation resulting from specific P2Y12
blockade by a specific antagonist of the P2Y12 receptor
(AR-C69931MX) [6]. This test gives reliable results in
whole blood samples kept at room temperature for up to
48 h [6,21]. Aspirin and abciximab did not interfere with
VASP phosphorylation [9,19]. A flow cytometric analysis
of VASP phosphorylation can be recommended as an
index (the gold standard) of the efficacy of P2Y12 inhibi-
tors [21].
Conclusion
In patients with planned elective PCI a flow cytometric
VASP phosphorylation test will identify those without suf-
ficient P2Y12 receptors inhibition and with risk of stent
thrombosis. In patients with no response to the clopidog-
rel loading dose, prasugrel seems to be an effective alter-
native.
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